{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:36:48Z","timestamp":1794199008405,"version":"4.8.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.eprac.2022.10.007","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T13:01:03Z","timestamp":1666270863000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Clarissa Elysia","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-1569","authenticated-orcid":false,"given":"Cheng Han","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Ning","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai En","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Nah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley Huey Shin","family":"Bong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khin Maung","family":"Win","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung Hlaing","family":"Bwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Hui","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Jun Hao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Wenling","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.P.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shadab","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude A.","family":"Oben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2022.10.007_bib1","doi-asserted-by":"crossref","unstructured":"Lim GEH, Tang A, Ng CH, et\u00a0al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. Published online December 4, 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.038","DOI":"10.1016\/j.cgh.2021.11.038"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.007_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Article","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.007_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.eprac.2022.10.007_bib4","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.16808","article-title":"Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis","volume":"55","author":"Ng","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.10.007_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/liv.14355","article-title":"Current management of non-alcoholic steatohepatitis","volume":"40","author":"Muthiah","year":"2020","journal-title":"Liver Int"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2022.10.007_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14521","article-title":"A\u00a0clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications\u2014what the non-specialist needs to know","volume":"24","author":"Muthiah","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2022.10.007_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.007_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.007_bib9","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.eprac.2022.10.007_bib10","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.eprac.2022.10.007_bib11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.007_bib13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.eprac.2022.10.007_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.eprac.2022.10.007_bib15","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.eprac.2022.10.007_bib16","doi-asserted-by":"crossref","unstructured":"Ng CH, Lim WH, Hui Lim GE, et\u00a0al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. Published online May 2, 2022. https:\/\/doi.org\/10.1016\/j.cgh.2022.04.014","DOI":"10.1016\/j.cgh.2022.04.014"},{"key":"10.1016\/j.eprac.2022.10.007_bib17","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sc Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.007_bib18","article-title":"Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis","volume":"9","author":"Liu","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.eprac.2022.10.007_bib19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.15673","article-title":"Modelling NAFLD disease burden in four Asian regions\u20142019-2030","volume":"51","author":"Estes","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eprac.2022.10.007_bib20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2022.10.007_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.wneu.2021.09.034","article-title":"Tenets for the proper conduct and use of meta-analyses: a practical guide for neurosurgeons","volume":"161","author":"Lee","year":"2022","journal-title":"World Neurosurg"},{"key":"10.1016\/j.eprac.2022.10.007_bib22","article-title":"Checking reference lists to find additional studies for systematic reviews","volume":"8","author":"Horsley","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eprac.2022.10.007_bib23","doi-asserted-by":"crossref","first-page":"d6891","DOI":"10.1136\/bmj.d6891","article-title":"Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study","volume":"343","author":"Lazo","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.007_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"10.1016\/j.eprac.2022.10.007_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7584","key":"10.1016\/j.eprac.2022.10.007_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/bmj.39057.406644.68","article-title":"What is heterogeneity and is it important?","volume":"334","author":"Fletcher","year":"2007","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"issue":"12","key":"10.1016\/j.eprac.2022.10.007_bib28","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/sim.3602","article-title":"Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses","volume":"29","author":"Jackson","year":"2010","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jrsm.1053","article-title":"GOSH\u2014a graphical display of study heterogeneity","volume":"3","author":"Olkin","year":"2012","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence","volume":"3","author":"Munn","year":"2014","journal-title":"Int J Health Policy Manag"},{"issue":"7109","key":"10.1016\/j.eprac.2022.10.007_bib31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.007_bib32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.31040","article-title":"Attributable fractions of nonalcoholic fatty liver disease for mortality in the United States: results from the third national health and nutrition examination survey with 27 years of follow-up","volume":"72","author":"Alvarez","year":"2020","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.eprac.2022.10.007_bib33","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ajg.2010.18","article-title":"Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study","volume":"105","author":"Adams","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.007_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/joim.13069","article-title":"Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016","volume":"288","author":"Zou","year":"2020","journal-title":"J\u00a0Intern Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.007_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2022.10.007_bib37","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2022.10.007_bib38","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.007_bib39","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.32519","article-title":"Risk of cardiovascular disease and loss in life expectancy in NAFLD","volume":"76","author":"Shang","year":"2022","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.eprac.2022.10.007_bib40","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.cgh.2017.11.026","article-title":"Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men","volume":"16","author":"Hwang","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.eprac.2022.10.007_bib41","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5009\/gnl210167","article-title":"Innovative Target Exploration of NAFLD (ITEN) Consortium. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease","volume":"16","author":"Moon","year":"2022","journal-title":"Gut Liver"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.007_bib43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2337\/dc17-1590","article-title":"Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission","volume":"41","author":"Wild","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.10.007_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027379","article-title":"Fatty liver and mortality: a cohort population study in South Italy","volume":"9","author":"Caruso","year":"2019","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.eprac.2022.10.007_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241357","article-title":"Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors","volume":"15","author":"Mann","year":"2020","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/liv.15171","article-title":"The burden of NAFLD in type 2 diabetic subjects from the general population: a Nationwide population-based follow-up study (NASHCO)","volume":"42","author":"Nabi","year":"2022","journal-title":"Liver Int"},{"issue":"10319","key":"10.1016\/j.eprac.2022.10.007_bib47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eprac.2022.10.007_bib48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11883-022-01027-5","article-title":"Comprehensive review and updates on holistic approach towards non-alcoholic fatty liver disease management with cardiovascular disease","volume":"24","author":"Chew","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.eprac.2022.10.007_bib49","doi-asserted-by":"crossref","unstructured":"Toh JZK, Pan XH, Tay PWL, et\u00a0al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. Published online September 22, 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.09.021","DOI":"10.1016\/j.cgh.2021.09.021"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3350\/cmh.2021.0406","article-title":"NAFLD increases risk of carotid atherosclerosis and ischemic stroke. an updated meta-analysis with 135,602 individuals","volume":"28","author":"Tang","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.007_bib51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.007_bib52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.007_bib53","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/liv.13031","article-title":"The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment","volume":"36","author":"Margini","year":"2016","journal-title":"Liver Int"},{"issue":"16","key":"10.1016\/j.eprac.2022.10.007_bib54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J Hepatol"},{"issue":"12","key":"10.1016\/j.eprac.2022.10.007_bib55","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3390\/biomedicines9121913","article-title":"NASH and Systemic complications: from basic to clinical research","volume":"9","author":"Baumgartner","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.007_bib56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12876-022-02290-1","article-title":"Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups","volume":"22","author":"Sugiyama","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.007_bib57","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.007_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.007_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eprac.2021.09.013","article-title":"Antidiabetic medications for type 2 diabetics with nonalcoholic fatty liver disease: evidence from a network meta-analysis of randomized controlled trials","volume":"28","author":"Ng","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2022.10.007_bib60","doi-asserted-by":"crossref","unstructured":"Xiao J, Ng CH, Chin Y-H, et\u00a0al. A class effect network meta-analysis of lipid modulation in non-alcoholic steatohepatitis for dyslipidemia. J Clin Transl Hepatol. Published online May 31, 2022. https:\/\/doi.org\/10.14218\/JCTH.2022.00095","DOI":"10.14218\/JCTH.2022.00095"},{"issue":"6","key":"10.1016\/j.eprac.2022.10.007_bib61","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/hep.32081","article-title":"Multidisciplinary clinic models: a paradigm of care for management of NAFLD","volume":"74","author":"Kumar","year":"2021","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.eprac.2022.10.007_bib62","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","article-title":"Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.007_bib63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/flgastro-2018-101155","article-title":"A\u00a0multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health","volume":"10","author":"Moolla","year":"2019","journal-title":"Frontline Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.007_bib64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.007_bib65","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/apt.15679","article-title":"Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data","volume":"51","author":"Loomba","year":"2020","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22006486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22006486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:14:38Z","timestamp":1761516878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22006486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1530891X22006486"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.10.007","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}